DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Gra
This is a multicenter, open-label study of DB107-RRV (formerly Toca 511) and DB107-FC (formerly Toca FC) when administered following surgical resection in newly diagnosed High Grade Glioma (HGG) patients. The study is designed to evaluate whether treatment with DB107-RRV in combination with DB107-FC when added to stand
| Condition(s) | High Grade Glioma, MGMT-Unmethylated Glioblastoma, MGMT-Methylated Glioblastoma |
|---|---|
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Study type | Interventional |
| Summary | This is a multicenter, open-label study of DB107-RRV (formerly Toca 511) and DB107-FC (formerly Toca FC) when administered following surgical resection in newly diagnosed High Grade Glioma (HGG) patients. The study is designed to evaluate whether treatment with DB107-RRV in combination with DB107-FC when added to standard of care provides clinical benefit to newly diagnosed HGG when compared to historical performance previously determined in well controlled clinical trials published in the peer reviewed literature. This study is going to be conducted in newly diagnosed HGG patients receiving with maximum surgical resection treatment followed by radiation and temozolomide treatment using the established Stupp Protocol for O6-methylguanine-DNA methyl-transferase (MGMT) methylated patients or |
| Who can participate | Inclusion Criteria: Each patient must meet all of the following inclusion criteria to be eligible for study entry: 1. Participant has provided written informed consent. 2. Participant is between 18 years of age and 75 years of age, inclusive. 3. Participant must have a Karnofsky Performance Scale (KPS) of \>= 70. 4. Participant must have newly diagnosed adult-type diffuse gliomas (World Health Organization Classification 2021) that has not been previously treated with surgery, radiation or chemotherapy (specifically astrocytoma, Isocitrate dehydrogenase (IDH)-mutant or glioblastoma, IDH-wildtype). 5. Based on the pre-operative evaluation by neurosurgeon, participant is a candidate for \>= 80% resection of the enhancing region. 6. The primary tumor must be made available for central testing |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | University of California, San Francisco |
| Locations | Los Angeles, California, United States; San Diego, California, United States; San Francisco, California, United States; Miami, Florida, United States; Lake Success, New York, United States |
| Start date | 2025-01-08 |
| NCT ID | NCT06504381 |
| Official listing | https://clinicaltrials.gov/study/NCT06504381 |